Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV Lytic Reactivation Therapy with PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07138989Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valganciclovir in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
valganciclovir
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07138989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138989.